|Bid||111.99 x 900|
|Ask||121.41 x 900|
|Day's Range||117.05 - 121.53|
|52 Week Range||60.27 - 125.72|
|Beta (5Y Monthly)||2.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||124.95|
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Sanofi’s new CEO laid out plans Tuesday to shake up one of the Bay State’s biggest drug companies, potentially throwing its 3-year-old diabetes-focused startup Onduo for a loop.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
Shares of The Medicines Company were up nearly 23% on Monday after Novartis said Sunday that it had agreed to buy the single-drug, clinical-stage biotech company for $85 per share.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, is hosting an R&D Day in New York City today. During the event, the Company plans to discuss its commercial and R&D progress, including its product and pipeline goals for 2020, focusing on the potential for global approval and/or commercialization of four RNAi therapeutic products and the advancement of six late-stage investigational programs.
Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
Shares of Alnylam Pharmaceuticals Inc. were up 9% in afternoon trading after the Food and Drug Administration approved Givlaari, its treatment for acute hepatic porphyria, a rare, genetic metabolic disorder. Patients in the clinical trial who took the drug had fewer porphyria attacks than patients taking a placebo. The annual list price for Givlaari is $575,000 and is dependent on a patient's weight. The biopharmaceutical company also said Wednesday that it has reached a value-based agreement in principle with Harvard Pilgrim, in which the health plan will pay full price for the therapy only if the real-world results match the trials. There are about 3,000 potential patients who have been diagnosed with the genetic disease in the U.S. and Europe, making it an ultra-rare orphan disease. (An orphan disease affects fewer than 200,000 people worldwide.) Alnylam stock has jumped 50% year-to-date, while the S&P 500 has rallied 24%.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, is announcing today a new and enhanced framework for value-based agreements (VBAs) designed to help patients with acute hepatic porphyria (AHP) – an ultra-rare orphan disease – gain access to GIVLAARI™ (givosiran) injection for subcutaneous use, a first-of-its-kind RNAi therapeutic for the treatment of AHP. Approved today by the U.S. Food and Drug Administration (FDA), GIVLAARI is indicated for the treatment of adults with AHP. Alnylam is in active discussions with leading payers about VBAs for GIVLAARI and plans to incorporate this new ultra-rare disease framework into these discussions and negotiations.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved GIVLAARI™ (givosiran) injection for subcutaneous use for the treatment of adults with acute hepatic porphyria (AHP). AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life. Long-term complications of AHP can include chronic neuropathic pain, hypertension, chronic kidney disease and liver disease.
Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval on Wednesday. The drug, Givlaari, uses a Nobel Prize-winning mechanism known as RNA interference to target and "silence" specific genetic material and is the second such drug to be approved http://bit.ly/37oqz9Z by the U.S. Food and Drug Administration. The injection, which is dosed based on patient weight, will be available after discounts at $442,000 per year and is approved for acute hepatic porphyria (AHP), a rare disorder that can lead to severe pain and paralysis, respiratory failure and seizures.